OncoMatch/Clinical Trials/NCT07232524
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Is NCT07232524 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies BL-M24D1 for head and neck squamous cell carcinoma.
Treatment: BL-M24D1 — This study is an open, multicenter, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic head and neck squamous cell carcinoma and other solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: allowed if >4 weeks or >5 half-lives prior to first dose
Use of chemotherapy ... within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: biotherapy
Exception: allowed if >4 weeks or >5 half-lives prior to first dose
Use of ... biotherapy ... within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: immunotherapy
Exception: allowed if >4 weeks or >5 half-lives prior to first dose
Use of ... immunotherapy within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: anthracycline
Exception: cumulative dose must not exceed 360 mg/m² during prior (neo)adjuvant anthracycline therapy
Cumulative anthracycline dose >360 mg/m² during prior (neo)adjuvant anthracycline therapy
Lab requirements
Blood counts
Toxicities from prior antitumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0
Kidney function
Liver function
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; QT interval prolongation, complete left bundle branch block, or third-degree atrioventricular block excluded; History of severe heart disease excluded
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; QT interval prolongation, complete left bundle branch block, or third-degree atrioventricular block [excluded]; History of severe heart disease [excluded]; Organ function levels must meet the requirements; Coagulation function: International Normalized Ratio ≤1.5, and activated partial thromboplastin time ≤1.5 × ULN; Urine protein ≤2+ or ≤1000mg/24h
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07232524 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, biotherapy, immunotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages